450 related articles for article (PubMed ID: 28100254)
1. Challenges in orphan drug development and regulatory policy in China.
Cheng A; Xie Z
Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
[TBL] [Abstract][Full Text] [Related]
2. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
3. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
[TBL] [Abstract][Full Text] [Related]
4. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
[TBL] [Abstract][Full Text] [Related]
6. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
7. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
Bannister JB
Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
[TBL] [Abstract][Full Text] [Related]
8. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
9. Orphan drug regulations. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
[TBL] [Abstract][Full Text] [Related]
10. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
11. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
12. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
13. Ethical considerations in orphan drug approval and use.
Kesselheim AS
Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
[TBL] [Abstract][Full Text] [Related]
14. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
15. The routes to orphan drug designation--our recent experience at the FDA.
Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
[No Abstract] [Full Text] [Related]
16. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
18. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
Gorzelany JA; de Souza MP
Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
[TBL] [Abstract][Full Text] [Related]
19. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
20. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]